Skip to main content
. Author manuscript; available in PMC: 2011 Sep 27.
Published in final edited form as: Br J Haematol. 2009 Sep 22;147(4):515–525. doi: 10.1111/j.1365-2141.2009.07887.x

Fig 4. Immunoreactivity of HDAC1 in colon carcinoma, HDAC6 in breast cancer, HDAC8 in leiomyosarcoma, and HDAC10 in hepatocellularcarcinoma.

Fig 4

These tissues were used as positive control for the specified antibodies.